H.U.Gugle Biotech Profile
Key Indicators
- Authorised Capital ₹ 2.00 M
as on 16-11-2024
- Paid Up Capital ₹ 2.00 M
as on 16-11-2024
- Company Age 21 Year, 5 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 1.35 Cr
as on 16-11-2024
- Satisfied Charges ₹ 6.00 M
as on 16-11-2024
- Revenue 53.03%
(FY 2023)
- Profit 127.34%
(FY 2023)
- Ebitda 54.95%
(FY 2023)
- Net Worth 40.74%
(FY 2023)
- Total Assets 3.39%
(FY 2023)
About H.U.Gugle Biotech
The Company is engaged in the Agriculture Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 2.00 M and a paid-up capital of Rs 2.00 M.
The company currently has active open charges totaling ₹1.35 Cr. The company has closed loans amounting to ₹6.00 M, as per Ministry of Corporate Affairs (MCA) records.
Shailesh Kathariya and Sanjay Gugle serve as directors at the Company.
- CIN/LLPIN
U73100KA2003PTC032149
- Company No.
032149
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
24 Jun 2003
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Bangalore
Industry
Company Details
- Location
Bangaluru, Karnataka, India
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at H.U.Gugle Biotech?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Shailesh Kathariya  | Director | 24-Jun-2003 | Current |
| Sanjay Gugle | Director | 30-Nov-2016 | Current |
Financial of H.U.Gugle Biotech.
H.U.Gugle Biotech Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 53.03% increase. The company also saw a substantial improvement in profitability, with a 127.34% increase in profit. The company's net worth Soared by an impressive increase of 40.74%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of H.U.Gugle Biotech?
In 2023, H.U.Gugle Biotech had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Hdfc Bank Limited Creation Date: 28 Feb 2015 | ₹1.00 M | Open |
Hdfc Bank Limited Creation Date: 26 May 2010 | ₹1.25 Cr | Open |
State Bank Of India Creation Date: 04 Jan 2005 | ₹6.00 M | Satisfied |
How Many Employees Work at H.U.Gugle Biotech?
H.U.Gugle Biotech has a workforce of 26 employees as of Apr 06, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of H.U.Gugle Biotech, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped H.U.Gugle Biotech's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
